Made on
Aug 1, 2026
Price at call
$47.08
6-month call
Bull +18.5%
Target by Feb 2027
$55.80
Great value below
$45.00
Model
v0.6.0
Projection vs Actual (6M history + forecast)
Forecast Change
+18.5% to $55.80
Predicted High
$55.80
at 6 months
Predicted Low
$47.80
in 2 weeks
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded. Predicted Aug 1, 2026 1:02 am
Bull
NVO trends higher to
$55.80
(+18.5% from $47.08)
by Feb 2027.
dip-then-recover
ThesisNVO is deeply discounted with valuation anchors well above spot and positive near-term catalysts (EU Wegovy pill, access deal) that should catalyze a bounce, but GLP-1 competitive pressure caps the rerating. Path drifts up as sentiment stabilizes and value gravity pulls toward mid-50s, short of full fair value.
Invalidated ifBreak below $44 on Lilly share-gain data or a Wegovy pill setback would invalidate; conversely a sharp rip above $60 pre-catalyst would front-run this path.
| Checkpointtime after the call | Datewhen it gets graded | Predictedthe claim: closing price | Current priceactual close — fills in over time | Predicted returnpredicted vs $47.08 at call | Conv.brain's confidence, 1–10 | Driverwhy the brain put the point here |
|---|---|---|---|---|---|---|
| Prediction made | Aug 1, 2026 | — | $47.08 at call | — | — | The anchor — every point below is measured from this price and date. |
| 2 weeks | Aug 15, 2026 | $43.67–$50.49 typical range · internal point $47.80 | — | ±7.2% | 7/10 | Low-beta drift, oversold bounce off catalysts |
| What actually happened: closed $45.89 on Aug 14, 2026 = -2.5% vs the call (predicted +1.5%) · direction HIT (called flat, was flat) · off by 4.1 pp · accuracy 8/10 · typical range ±7.2%: inside the band · S&P +4.0% over the same window — beat it | ||||||
| 1 month | Sep 1, 2026 | $42.14–$52.02 typical range · internal point $48.90 | — | ±10.5% | 6/10 | Sentiment stabilizes as access deal digested |
| What actually happened: closed $45.12 on Sep 1, 2026 = -4.2% vs the call (predicted +3.9%) · direction HIT (called flat, was flat) · off by 8.0 pp · accuracy 7/10 · typical range ±10.5%: inside the band · S&P +1.9% over the same window — lagged it | ||||||
| 2 months | Oct 1, 2026 | $50.50 | — | +7.3% | 5/10 | Value buyers step in below fair value |
| What actually happened: closed $37.91 on Sep 30, 2026 = -19.5% vs the call (predicted +7.3%) · direction MISS (called up, was down) · off by 26.7 pp · accuracy 3/10 · S&P +2.2% over the same window — lagged it | ||||||
| 3 months | Nov 1, 2026 | $52.20 | — | +10.9% | 5/10 | EU Wegovy pill approval optionality builds |
| 4 months | Dec 1, 2026 | $53.80 | — | +14.3% | 4/10 | Year-end positioning into GLP-1 recovery trade |
| 5 months | Jan 1, 2027 | $54.90 | — | +16.6% | 4/10 | Gradual rerate toward DCF anchor |
| 6 months | Feb 1, 2027 | $55.80 | — | +18.5% | 4/10 | Converges near deterministic baseline endpoint |
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets $55.95 (+18.8%) — both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it. Brain: claude-opus-4-7.
Weaknesses
No weaknesses recorded for this run.All inputs present, no fallbacks used — nothing to flag.
Equation Inputs
Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.Value anchors (from deep analysis)
| Price at call | $47.08 |
| Composite fair value | $65.61 |
| Signal-adjusted fair value | $75.39 |
| DCF fair value | $63.23 |
| Anchored-PE fair value | $94.39 |
| Buy-below (value lens) | $45.00 |
| Value net score | +24 |
| Value confidence | 6 / 10 |
| Quality net score | +59 |
| Memo confidence | 7 / 10 |
| Deserved value (base) | — |
| Quality tilt | — |
| Deserved value (used) | — |
| Coherence (value × quality) | — |
Price behaviour (trailing — shapes the realism line)
| Realized volatility (annualized) | 1m 41.5% 3m 36.4% 6m 52.0% |
| Daily σ (realism noise) | 2.3% |
| Beta vs S&P 500 | 1m -0.49 3m 0.02 5m 0.66 |
| Trailing 6-month return | -20.6% |
Knobs (equation params)
| ladder | ["w2","m1","m2","m3","m4","m5","m6"] |
| llm_model | claude-opus-4-7 |
| max_tokens | 3000 |
| control_knobs | {"w_dcf":0.5,"k_qual":0.200000000000000011102230246251565404236316680908203125,"reach_6m":0.450000000000000011102230246251565404236316680908203125,"coh_floor":0.5,"conf_gain":0.059999999999999997779553950749686919152736663818359375,"noise_phi":0.84999999999999997779553950749686919152736663818359375,"conf_floor":0.40000000000000002220446049250313080847263336181640625,"w_composite":0.5,"noise_window":"3m","flat_band_pct":5,"horizon_months":6,"noise_sigma_fallback":0.01499999999999999944488848768742172978818416595458984375} |
| Neutral band (%) | 5 |
| earnings_brief | v1 |
| prompt_version | p1 |
| control_version | v0.3.0 |
Version & Tech Chain
What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model
v0.6.0
#271041f8fcd5 Tech composition (what this version is built from)
| # | Process | Kind | Group |
|---|---|---|---|
| 1 | Synthesis valuation-synthesis |
deterministic | final |
| 2 | Scenario Analysis scenario-valuation |
deterministic | valuation |
| 3 | Valuation / Mispricing ext-lens-value |
llm | extended |
| 4 | Company Quality ext-lens-quality |
llm | extended |
| 5 | Forensic Memo (combiner) ext-forensic-memo |
llm | extended |
| 6 | Classification company-classification |
llm | foundation |
| 7 | Live Quote fmp-quote |
data | market-data |
Inputs used (the runs that fed this prediction)
| Upstream process | Ran | Lag | Run id |
|---|---|---|---|
company-classification |
Jul 30, 2026 | freshest | NVO-20260730-180604-92c8 |
ext-forensic-memo |
Jul 30, 2026 | freshest | ext-NVO-20260730-183807-3f47 |
ext-lens-quality |
Jul 30, 2026 | freshest | ext-NVO-20260730-183807-3f47 |
ext-lens-sentiment |
Jul 30, 2026 | freshest | ext-NVO-20260730-183807-3f47 |
ext-lens-value |
Jul 30, 2026 | freshest | ext-NVO-20260730-183807-3f47 |
scenario-valuation |
Jul 30, 2026 | freshest | NVO-20260730-180604-92c8 |
valuation-synthesis |
Jul 31, 2026 | freshest | NVO-20260730-180604-92c8 |
Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.
Saved History
6 frozen snapshots — the record we score once predictions mature.| Made | Model | Call | At call | Target | Exp. | Eval due | |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | v0.6.0 | Bull | $46.07 | $51.00 | +10.7% | Feb 2027 | view |
| Aug 25, 2026 | v0.6.0 | Bull | $48.12 | $54.50 | +13.3% | Feb 2027 | view |
| Aug 20, 2026 | v0.6.0 | Bull | $46.42 | $53.40 | +15.0% | Feb 2027 | view |
| Aug 14, 2026 | v0.6.0 | Bull | $46.72 | $52.40 | +12.2% | Feb 2027 | view |
| Aug 6, 2026 | v0.6.0 | Bull | $44.53 | $51.50 | +15.7% | Feb 2027 | view |
| Aug 1, 2026 | v0.6.0 | Bull | $47.08 | $55.80 | +18.5% | Feb 2027 | viewing |
Not Yet Modeled
What this v0.6.0 forecast deliberately ignores — the work ahead, in plain sight.- Scenario probabilities — one path, no bull/bear split (base_prob = 1.0).
- Intraday / sub-2-week behaviour — the first claim is at 14 days by design (EOD product).
- Position sizing / portfolio context — the path is a price claim only.